{
  "url": "https://www.law.cornell.edu/regulations/new-york/8-NYCRR-63.17",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 8 § 63.17 - Administering injectable medications pursuant to patient-specific prescriptions or patient-specific orders and emergency treatment of anaphylaxis",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 8 § 63.17 - Administering injectable medications pursuant to patient-specific prescriptions or patient-specific orders and emergency treatment of anaphylaxis\n\nState Regulations\n(a) Definitions. As used in this section: (1)\n\nInjectable medication shall mean injectable medications approved by the Federal\n\nFood and Drug Administration for the treatment of mental health and substance\nuse disorder. (2)\n\nCertified\npharmacy intern shall mean a pharmacy intern as defined in Education Law § 6806\nwho has met the requirements set forth in section\n63.4\n(d) of this\n\nPart and has been issued a certificate of administration by the department\npursuant to section\n63.9\n(a)(3)\nof this\n\nPart. (b) Injection of\nmedications. (1)\n\nPursuant to Education Law §\n6802(22), a certified pharmacist shall be authorized to administer injectable\nmedications to patients for the treatment of mental health and substance use\ndisorder provided that: (i) the pharmacist has\nreceived training as prescribed in Education Law § 6801(3) and has been issued\na certificate of administration issued by the department pursuant to section\n63.9\n(a)(3)\nof this\n\nPart; (ii)\nthe administration of\nthe injectable medication is conducted pursuant to a valid patient-specific\nprescription or patient-specific order; (iii)\nthe pharmacist has maintained continued\ncompetency regarding the populations served and medications available for\nadministration; and\n(iv)\nthe\ninjectable medications are approved by the Federal Food and Drug Administration\nfor the treatment of mental health and substance use disorder. (2)\n\nWith the exception of a\ncertified pharmacy intern, a certified pharmacist shall not delegate the\nadministration of an injectable medication to another person. When\nadministering an injectable medication, the certified pharmacy intern shall be\nunder the immediate personal supervision of the certified pharmacist. Administration by a certified pharmacy intern shall not occur unless the\npatient has been informed and has consented to such administration. If the\npatient does not consent to the administration of an injectable medication by a\ncertified pharmacy intern, a certified pharmacist shall be present to\nadminister the injectable medication to the patient. (3)\n\nPrior to administering an injectable\nmedication each certified pharmacist shall: (i) verify that the patient has already\nreceived an initial dose of the injectable medication and has been deemed\neligible for maintenance treatment by their prescriber. Such eligibility shall\nbe communicated by the prescriber in writing, electronically or via facsimile. Where such means of communication are not possible, a prescriber may\ncommunicate patient eligibility to a pharmacist verbally, provided that the\npharmacist documents such communication within the patient's medication profile\nas defined in section\n63.6\n(b)(7)\nof this\n\nPart; (ii)\ninform the patient, or\nthe person legally responsible for the patient when the patient is incapable of\nconsenting to the administration of the injectable medication, of the\ninjectable medication's common side effects, drug interactions, injection site\nreactions and other information that is routinely provided to patients upon the\ndispensing of a medication. Such information shall be provided orally and in\nwriting; (iii)\nassess the patient\nfor any contraindications to the injectable medication; (iv)\nbe responsible for having emergency\nanaphylaxis treatment agents, related syringes and needles available at the\nlocation where the injectable medication is being administered; (v) obtain written consent from the patient\nto administer the injectable medication. If the patient is incapable of\nproviding written consent, it may be obtained from the person legally\nresponsible for the patient. For the purposes of this section, such consent\nshall be obtained in writing or electronically and noted within the patient's\nmedication profile as defined in section\n63.6\n(b)(7)\nof this\n\nPart; (vi)\nprovide the patient, or\nperson legally responsible for the patient if the patient is not able to\nconsent to the administration of the injectable medication, with written\ninstructions regarding the course of action to be taken if an adverse reaction\nor contraindication occurs; and\n(vii)\nprovide an area that ensures patient\nprivacy when administering the injectable medication. (4)\n\nReporting of injectable medications: (i) the certified pharmacist or the\npharmacist's designee shall notify the patient's prescriber within five days of\nadministering the injectable medication. Such notification may occur via an\nelectronic medical records system, an electronic prescribing technology or\npharmacy records, facsimile, electronic transmission or other electronic means. If an electronic means is not available to communicate the administration of\nthe injectable medication, a certified pharmacist or their designee may\ncommunicate the information via telephone. Such notification shall be\ndocumented in the patient's medication profile as defined in section\n63.6\n(b)(7)\nof this\n\nPart. (ii)\nin the event that the\npatient does not receive their scheduled injectable medication, the certified\npharmacist shall notify the patient's prescriber within 72 hours after the\ninjectable medication was scheduled to be administered. (iii)\n\nIf the patient experiences any side\neffects or adverse reactions to the medications the certified pharmacist shall\nnotify the prescriber immediately and make themselves available to discuss the\nadverse reaction with the patient's prescriber. (b) Anaphylaxis treatment agents. (1)\n\nEach certified pharmacist who receives\ntraining as prescribed in Education Law § 6801(3) and is issued a certificate\nof administration pursuant to section\n63.9\n(a)(3)\nof this\n\nPart shall be authorized to administer medications for the treatment of\nanaphylaxis to patients receiving injectable medications. (2)\neach certified pharmacist who administers\nmedication for the treatment of anaphylaxis to patients receiving an injectable\nmedication shall follow the standards, procedures and reporting requirements\nfor the administration of anaphylactic medication set forth in section\n63.9\n(b) of this\n\nPart. (c) Nothing in\nthis section shall prevent a certified pharmacist from refusing to administer\nan injectable medication if, in their professional judgment, potential adverse\neffects, interactions, or other therapeutic complications could endanger the\nhealth of a patient. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 8\n§\n63.17\n\nAdopted\n\nNew\n\nYork State Register June 26, 2024/Volume XLVI, Issue 26, eff. 6/10/2024, exp. 8/8/2024\n(Emergency)\n\nAmended\n\nNew\n\nYork State Register July 31, 2024/Volume XLVI, Issue 31, eff. 7/31/2024\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 15126
}